After Sanofi leadership telegraphed an upsized appetite for business development last month, signals have emerged that the ...
The FDA's complete response letter for Summit Therapeutics and Akeso's ivonescimab reveals more grievances than just an ...
Merck & Co. has delivered a one-two legal punch against Halozyme Therapeutics, clearing major commercialization hurdles for ...
Though the quest to locate the regulator’s next commissioner hit a snag this week, the FDA has nevertheless been bringing ...
Facing an extended drought of options, patients with type 3 Gaucher disease (GD3) are getting a new treatment that's also the ...
Speaking on a press call ahead of Thursday’s investor presentation, CEO Vas Narasimhan attributed the lower growth target to ...
Novo will trim 215 jobs reporting to its New Jersey headquarters starting in February as part of a "redesign" of its U.S.
The FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class ...
The FDA has slammed Johnson & Johnson over misleading claims about its bladder cancer drug Inlexzo, accusing the pharma ...
Salerno Pharmaceuticals of Tulsa, Oklahoma, is facing pressure from the FDA to yank its lone commercial product. | In a ...
Biogen is visualizing life amid disease progression in its newest Friedreich ataxia (FA)-focused campaign, reminding ...
The FDA has quietly shelved the Commissioner’s National Priority Voucher (CNPV) pilot program, a controversial speedy review ...